Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,737.40
+5.30 (0.31%)
Nov 13, 2025, 3:29 PM IST
Sun Pharmaceutical Industries Employees
Sun Pharmaceutical Industries had 43,000 employees as of March 31, 2025. The number of employees did not change compared to the previous year.
Employees
43,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
12.78M INR
Profits / Employee
2.43M INR
Market Cap
4.16T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 43,000 | 0 | - |
| Mar 31, 2024 | 43,000 | 2,000 | 4.88% |
| Mar 31, 2023 | 41,000 | 3,000 | 7.89% |
| Mar 31, 2022 | 38,000 | 1,000 | 2.70% |
| Mar 31, 2021 | 37,000 | 1,000 | 2.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Apollo Hospitals Enterprise | 42,497 |
| Cipla | 30,313 |
| Zydus Lifesciences | 27,917 |
| Aurobindo Pharma | 27,707 |
| Mankind Pharma | 26,978 |
| Alkem Laboratories | 18,785 |
| Biocon | 16,315 |
| Glenmark Pharmaceuticals | 15,800 |
Sun Pharmaceutical Industries News
- 1 day ago - Why are Sun Pharma shares falling today? Explained - Business Upturn
- 1 day ago - Sun Pharma’s partner Philogen reports positive survival trends in Fibromun Phase III study for soft tissue sarcoma - Business Upturn
- 6 days ago - Sun Pharma share: Nomura upgrades to buy, expects 16% upside on strong branded generics growth and favourable risk-reward - Business Upturn
- 7 days ago - Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales ... - GuruFocus
- 7 days ago - Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript - GuruFocus
- 9 days ago - Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect - GuruFocus
- 23 days ago - Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout - Benzinga
- 5 weeks ago - Stocks to Watch Today, October 9: HFCL, Coal India, Prestige Estates, GR Infra, Lupin, Senco Gold, Saatvik Green, Adani Power, Sun Pharma in focus - Business Upturn